Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics
Portfolio Pulse from
Tharimmune, Inc. has been granted a European patent for its biodegradable polymeric nanoparticles, enhancing delivery of therapeutic antibodies and peptides, particularly in cancer therapies.
November 13, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tharimmune, Inc. has been granted a European patent for its biodegradable polymeric nanoparticles, which are designed to improve the delivery of therapeutic antibodies and peptides, especially in cancer therapies.
The granting of a European patent is a significant milestone for Tharimmune, as it validates their technology and potentially opens up new markets in Europe. This could lead to increased investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100